Summary:
- Oncology is the most expensive specialty in the US, with national spending projected to exceed $246 billion by 2030, and the Blue Cross Blue Shield of Massachusetts partnership with Thyme Care directly targets that trajectory by tying oncology reimbursement to patient health outcomes instead of service volume.
- Thyme Care's model has shown reductions in emergency room visits of as much as 40% in other partnerships, evidence the value-based approach can lower avoidable utilization for members with cancer.
- The model pairs financial accountability with a dedicated support system for members with a suspected or confirmed cancer diagnosis, addressing both the human and financial dimensions of the disease.
Read the full article here.